Navigation Links
Major rise in Caesarean sections linked to impaired womb function with age
Date:7/2/2008

Delaying childbirth has substantially contributed to recent rises in caesarean section rates, according to a paper published this week by scientists at Cambridge University.

The findings come from an analysis of a large body of Scottish data performed by a team under Professor Gordon Smith, at the University's Department of Obstetrics and Gynaecology.

The team examined more than 500,000 entries collected by the Scottish Morbidity Record between 1980 and 2005 to determine the association between maternal age and the outcome of labour. Alongside a major increase in the number of caesareans, they found striking changes in the age of mothers over the study period.

The proportion of women aged 35-39 entering their first pregnancy increased seven-fold, whilst there was a ten-fold increase for women aged 40 or older. At the same time, the caesarean rate more than doubled. The team estimate that 38% of these additional procedures would have been avoided if the maternal age distribution had remained static.

This picture is mirrored elsewhere in the developed world, which has seen a dramatic increase in caesarean sections over the past thirty years. Previous epidemiological studies had also reported a correlation with maternal age, but the reason for the increased rate remained unclear.

Hypothesising that there was a biological cause, the team went on to study samples of the myometrium, muscle from the middle of the uterine wall, taken from 62 women undergoing elective caesarean procedures in Cambridge.

They found that advancing age was associated with impaired uterine function, in particular a reduced degree of spontaneous contraction and change in the type of contraction. The reduction is thought to result in poor progression of labour and thus the increased rate of caesarean section.

The findings, which are published this week in Public Library of Science Medicine, will have implications for p
'/>"/>

Contact: Tom Russell
tom.russell@admin.cam.ac.uk
44-012-233-32300
University of Cambridge
Source:Eurekalert

Page: 1 2

Related medicine news :

1. J.D. Power and Associates Reports: A Vast Majority of Southern California Indian Gaming Casino Customers Express Desire for a Smoke-Free Environment
2. BRAVA Breast Enhancement System Hits Major Milestone
3. American Academy of Dermatology, Major League Baseball and Major League Baseball Players Association Play Sun Smart(TM) to Strike Out Skin Cancer
4. Building the New Majority Launches Grassroots GOP Effort in New Jersey
5. Major Associations Band Together to Urge Congressional Action on Tobacco Legislation
6. Report: NIH and Global Health Research are a Major Boon to All State Economies
7. Alijor.com Now Offers Price Summaries for Healthcare Services in Major U.S. Cities
8. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
9. Consumers Can Purchase Majority of Tomato Varieties
10. Majority of U.S. House Supports Repeal of Medicare Therapy Caps
11. SXC Health Solutions to provide technology services and support to major PBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... Lighthouse International and EHE International un...W YORK, Jan. 8 Thousand...e New Year that urges them to take care of their v...nd graciously donated by EHE International, was cr...leader in vision healthcare. It will be on display...
(Date:1/8/2009)...likely to be deadly for women and African-American...enomenon account for only part of the differences ... counterparts, according to results published in t...esults present a stark question for doctors and pa...se upon diagnosis don,t account for all the increa...
(Date:1/8/2009)...sets stage for productive partnership , , BALTI... Recovery Coalition (MARC), a broad-based group to...d the groundwork for improving the Medicare Second...with officials from the Center for Medicare and Me...introduce MARC as an industry resource to CMS and ...
(Date:1/8/2009)...ing an eye on pets during National Glaucoma month....ary 9, 2009 -- In recognition of National Glaucoma... spreading the word and increasing awareness of an...umans.    , , ,"When eyes...Noelle McNabb, DVM, Diplomate AVCO, a board certif...
Breaking Medicine News(10 mins):Health News:61 Million Americans are at Risk of Vision Loss and Don't Even Know It 2Health News:61 Million Americans are at Risk of Vision Loss and Don't Even Know It 3Health News:Why bladder cancer is deadlier for some 2Health News:Why bladder cancer is deadlier for some 3Health News:Why bladder cancer is deadlier for some 4Health News:MARC Coalition Holds Initial Meeting With CMS; Announces New Members 2Health News:Glaucoma Awareness Not Just for Humans 2Health News:Glaucoma Awareness Not Just for Humans 3
...r an urgent Food and Drug Administration assessmen...us, on Monday, but the FDA said there wasnt an imm...he sweetener may cause cancer. A new study publish... to the fact that aspartame can cause leukemia, ly...
...M), a clinical stage biopharmaceutical company dev...atment of cancer and hepatitis C virus infection, ...l designed to evaluate the safety and efficacy of ...in patients with glioblastoma multiforme (GBM), a ...
...ve agreement with Delmont Laboratory to introduce ... treats diseases of staphylococcal infection . Acc...ry will supply bulk materials and China Biopharma ... the final packaging in China. CBPC will also con...
...ined not to give up smoking because she believes t... Rouge star said that she is an occasional smoker ...the 39-year-old is sure that she will warn everyon...going to start not to get into the habit. "Yes, I...
Other Medicine News:Health News:Aspartame Probe Call Rejected by FDA 2Health News:Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial 2
(Date:1/8/2009)...reated at the initial dose in an ongoing Phase Ib ...ecline after three days , , Conference Call Tod...wire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (N...irst cohort of an ongoing Phase Ib clinical trial ...oside polymerase inhibitor. ANA598 was very well-...
(Date:1/7/2009)...everal Products in Development Based On Osteotech,...te Natural BioRegeneration; FDA Filing Anticipated...n. 7 Osteotech, Inc. (...f biologic products for regenerative healing, anno...al trial for its DuraTech(TM) BioRegeneration Matr...
(Date:1/6/2009)....Y., Jan. 6 In recent controlled s...ty of Memphis , scientists found that the patented... first and only proven ingredient to increase leve...asing blood nitrate/nitrate (NOx) in human subject...nables an increase in blood flow to the skeletal m...
(Date:1/6/2009)... France, January 6 , ... Collaboration Until,December 2011 , - Exp...e Antibody,Discovery in Ophthalmology , - ...f Allergan,Sublicenses to a Third Party , ...nounced a reinforcement,of its existing drug disc...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Dental Implants Need More Work Than Root Canals 30236 1Dental Implants Need More Work Than Root Canals 30236 2Epocrates Offers International Market Research Panel 30234 1Epocrates Offers International Market Research Panel 30234 2Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED 1077 30232 1Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED 1077 30232 2Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED 1077 30232 3Radius Raises Additional 2415 Million Increasing Second Private Equity Financing Round to 2482 5 Million 3463 1Radius Raises Additional 2415 Million Increasing Second Private Equity Financing Round to 2482 5 Million 3463 2
...l and Regulatory Development of Oral,Anti-Inflamma...wire-FirstCall/ -- Celgene,Corporation announced i...l anti-inflammatory candidates across a broad rang... an oral TNF,antagonist and anti-inflammatory agen...ellent side effect profile in a placebo,controlled...
...--May 22, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israe...ay data from its Phase I trial of BL-1020, the fir...for the treatment of,schizophrenia. The trial demo...demonstrated biochemical evidence of dopamine,bloc...esented the,data in a poster (Abstract 235 XX) at ...
Other Medicine Technology:Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases 2Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases 3Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases 4BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference 2BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference 3BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference 4
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation.
Elmed electrosurgical systems for major surgery.
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions.
Adson bipolar forceps, 12 cm, straight.
Medicine Products: